Huiyu Pharmaceutical announced that Huiyu Haiyue, a wholly-owned subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and clinical trials of injectable HY07121 for the treatment of advanced solid tumors were approved. This drug is an anti-PD-1, anti-TIGIT, IL-15/IL-15Rα three-target antibody fusion protein, and is a class 1 innovative therapeutic biological product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.